No Data
No Data
Companies Like Structure Therapeutics (NASDAQ:GPCR) Are In A Position To Invest In Growth
Cantor Fitzgerald Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $65
Express News | Cantor Fitzgerald Reiterates Overweight on Structure Therapeutics, Maintains $65 Price Target
Analysts Offer Insights on Healthcare Companies: Structure Therapeutics, Inc. Sponsored ADR (GPCR) and AbSci (ABSI)
Buy Rating Affirmed for Structure Therapeutics on Strong Pipeline and Undervalued Patent Portfolio
Deutsche Bank praises Eli Lilly and Co (LLY.US) as a "high-growth unicorn", with a target price skyrocketing to $1025.
Deutsche Bank has upgraded its rating on Eli Lilly and Co (LLY.US) from "hold" to "buy" with a target price increase from $725 to $1025.
No Data